首页> 外文期刊>Acta Virologica: International Journal >In vitro evaluation of a polytope DNA construct as a novel DNA vaccine strategy against human cytomegalovirus-associated diseases
【24h】

In vitro evaluation of a polytope DNA construct as a novel DNA vaccine strategy against human cytomegalovirus-associated diseases

机译:对Polytope DNA构建体的体外评估作为对人巨细胞病毒相关疾病的新型DNA疫苗策略

获取原文
获取原文并翻译 | 示例
       

摘要

Human cytomegalovirus (HCMV) establishes severe disease in fetus, newborn and immuno-compromised individuals. Polytope DNA vaccine strategy allows us to choose conserved and immunodominant epitopes from different antigens that can stimulate cellular and humoral immune responses simultaneously. In this study, a synthetic chimeric gene fragment was subcloned in to DNA vaccine vector pcDNA3.1+. The recombinant vector was transferred in to suitable eukaryotic cell line HEK 293T and the expression level of polytope construct from HEK 293T-infected cells was determined by western blot. These results show that there was no mutantion in target segment and recombinant vector showed significant levels of expression. Base on these results, using a proper procedure for design can cause expression and stability of polytope peptide.
机译:人巨细胞病毒(HCMV)在胎儿,新生儿和免疫损害的个体中建立严重疾病。 Polytope DNA疫苗策略使我们能够选择来自不同抗原的保守和免疫肿瘤表位,其可以同时刺激细胞和体液免疫应答。 在该研究中,将合成的嵌合基因片段亚克隆到DNA疫苗载体pcdna3.1 +中。 将重组载体转移到合适的真核细胞系HERK 293T中,通过Western印迹测定HEK 293T感染细胞的多托氏菌构建体的表达水平。 这些结果表明,靶段中没有脱节,重组载体显示出显着的表达水平。 基于这些结果,使用适当的设计程序会导致多托肽的表达和稳定性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号